Nicox extends cash runway
Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
The announcement of an extended cash runway and potential milestone payments provides NicOx with financial visibility beyond Q1 2028, reducing near-term liquidity risk and supporting its development programs. Positive sentiment for NicOx is tempered by the dependence on regulatory approval of NCX 470, while partners Kowa (company) and Ocumension may see limited direct impact from this update.
NicOx SA, an international ophthalmology company listed on Euronext Paris Growth Paris, announced on September 2, 2026 an extension of its cash runway and provided a corporate and financial update. As of 31 August 2026, NicOx had estimated cash and cash equivalents of EUR 8.4 million, up from EUR 4.1 million at the end of 2025, sufficient to fund existing operations beyond Q1 2028. The company expects that receipt of a milestone payment upon U.S. approval of its lead product NCX 470 (PDUFA date 30 April 2027) would extend funding into 2029, with subsequent royalties from an anticipated H2 2027 U.S. launch by partner Kowa (company) extending the runway further. NicOx also noted additional financing options under a Vester Finance shareholder loan announced in June 2026. In parallel, the company is pursuing business development discussions and evaluating strategic growth opportunities, including potential collaborations or business combinations. Management changes were announced: Doug Hubatsch transitioned from EVP and Chief Scientific Officer to Chief Scientific Advisor, while Siobhan Garbutt, VP and Head of Clinical Development, assumed leadership of the development team. NicOx's lead program NCX 470 is licensed to Paragon Therapeutics for Chinese, Korean and Southeast Asian markets and to Kowa (company) for the rest of the world. The company also has a preclinical program with Glaukos Corporation and commercial products VYZULTA and ZERVIATE licensed to Bausch Health — Bausch & Lomb and Harrow, Inc., among others.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard